Literature DB >> 27070953

Clinical Features of Systemic Metastatic Retinal Lymphoma in Japanese Patients.

Rumiko Taki1, Atsunobu Takeda1, Hiroshi Yoshikawa1, Takako Fukuhara1, Ryoichi Arita1, Yoko Suehiro2, Ilseung Choi2, Yuji Kumano3, Takao Nakamura4, Tatsuro Ishibashi1.   

Abstract

PURPOSE: Systemic metastatic retinal lymphoma (SMRL) originates in systemic organs. It has been reported to exhibit clinical features similar to those of primary vitreoretinal lymphoma (PVRL). We report six cases of SMRL in a single-center survey in Japan.
METHODS: The clinical and pathologic features in SMRL at the Kyushu University Hospital were retrospectively studied.
RESULTS: The mean patient age at the onset of ocular involvement was 75.3 years. Four patients had brain involvement. The primary sites were: breast (2); chest (1); testis (1); intestinal tract (1); and nasal sinus (1). In all patients, the cytology of vitreous samples indicated diffuse large B-cell lymphoma (DLBCL).
CONCLUSIONS: DLBCL is the most common subtype in our study. The prevalence of CNS involvement in patients with SMRL is similar to that with PVRL. The testis and breast may be common sites of origin for SMRL.

Entities:  

Keywords:  CNS involvement; Clinical features; primary organs; single-center study; vitreoretinal lymphoma

Mesh:

Substances:

Year:  2016        PMID: 27070953     DOI: 10.3109/09273948.2016.1151894

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma.

Authors:  Takako Ito; Atsunobu Takeda; Kohta Fujiwara; Eiichi Hasegawa; Shintaro Nakao; Yoshihiro Ohishi; Yoshinao Oda; Hiroshi Yoshikawa; Koh-Hei Sonoda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-13       Impact factor: 3.117

2.  Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.

Authors:  Anahita Sehgal; Jose S Pulido; Arman Mashayekhi; Tatyana Milman; Gabor Gy Deák
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.